Neuroendocrine liver metastasis from the small intestine: Is surgery beneficial for survival?
Livermetastasis
NEN
NET
Neuroendocrine neoplasia
Neuroendocrine tumors
Small intestine
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
14 01 2021
14 01 2021
Historique:
received:
11
11
2020
accepted:
05
01
2021
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
22
6
2021
Statut:
epublish
Résumé
Neuroendocrine neoplasia of the small intestine (siNEN) are frequently diagnosed with liver metastases. The impact of the presence of liver metastases on overall survival and the necessity of surgery for liver metastasis is discussed controversially. The aim of this study is to evaluate and compare the overall long-term survival of patients with siNENs with and without liver metastasis at initial diagnosis and the possible benefit of surgical treatment as compared to active surveillance of metastases. 123 consecutive patients with siNENs were treated between 1965 and 2016. All clinical and histological records were reevaluated including analysis of the proliferation rates in all specimens. The 1-, 5-, 10- and 20-year overall survival was estimated by Kaplan-Meier analysis for patients with and without liver metastasis and according to the type of treatment (surgical vs. surveillance) of liver metastases if present. The 1-, 5-, 10- and 20-year overall survival rate was 89.0%, 68.4%, 52.8% and 31.0% in patients without and 89.5%, 69.5%, 33.2% and 3.6% in those with liver metastases. No statistically significant differences were observed comparing the two groups. Within the group of patients with liver metastases, the type of treatment (surgical vs. surveillance) was in favor of patients undergoing surgery. Multivariate analysis showed that the presence of liver metastases upon diagnosis was an individual risk factor associated with worse survival. The presence of liver metastasis at initial diagnosis does not have a statistically significant influence on survival. Surgery for hepatic metastasis seems to show a benefit for overall survival and may be indicated especially in patients symptomatic due to high tumor burden and serotonin hypersecretion to reduce hormone activity.
Sections du résumé
BACKGROUND
Neuroendocrine neoplasia of the small intestine (siNEN) are frequently diagnosed with liver metastases. The impact of the presence of liver metastases on overall survival and the necessity of surgery for liver metastasis is discussed controversially. The aim of this study is to evaluate and compare the overall long-term survival of patients with siNENs with and without liver metastasis at initial diagnosis and the possible benefit of surgical treatment as compared to active surveillance of metastases. 123 consecutive patients with siNENs were treated between 1965 and 2016. All clinical and histological records were reevaluated including analysis of the proliferation rates in all specimens. The 1-, 5-, 10- and 20-year overall survival was estimated by Kaplan-Meier analysis for patients with and without liver metastasis and according to the type of treatment (surgical vs. surveillance) of liver metastases if present.
RESULTS
The 1-, 5-, 10- and 20-year overall survival rate was 89.0%, 68.4%, 52.8% and 31.0% in patients without and 89.5%, 69.5%, 33.2% and 3.6% in those with liver metastases. No statistically significant differences were observed comparing the two groups. Within the group of patients with liver metastases, the type of treatment (surgical vs. surveillance) was in favor of patients undergoing surgery. Multivariate analysis showed that the presence of liver metastases upon diagnosis was an individual risk factor associated with worse survival.
CONCLUSION
The presence of liver metastasis at initial diagnosis does not have a statistically significant influence on survival. Surgery for hepatic metastasis seems to show a benefit for overall survival and may be indicated especially in patients symptomatic due to high tumor burden and serotonin hypersecretion to reduce hormone activity.
Identifiants
pubmed: 33446229
doi: 10.1186/s13023-021-01677-9
pii: 10.1186/s13023-021-01677-9
pmc: PMC7809808
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
30Références
Anticancer Res. 2018 Mar;38(3):1267-1278
pubmed: 29491050
J Clin Oncol. 2008 Jun 20;26(18):3063-72
pubmed: 18565894
Visc Med. 2017 Oct;33(5):340-343
pubmed: 29177162
Int J Cancer. 2016 Dec 15;139(12):2679-2686
pubmed: 27553864
Neuroendocrinology. 2012;95(2):157-76
pubmed: 22262022
Neuroendocrinology. 2017 Feb 17;105(3):310-319
pubmed: 28222443
Endocr Relat Cancer. 2016 Mar;23(3):191-9
pubmed: 26743120
Surg Today. 2013 Oct;43(10):1168-74
pubmed: 23143168
J Clin Med. 2020 Jul 21;9(7):
pubmed: 32708330
Neuroendocrinology. 2017 Mar 29;105(3):266-280
pubmed: 28351033
Oncologist. 2011;16(5):602-13
pubmed: 21467149
Cancer. 2011 Aug 1;117(15):3332-41
pubmed: 21246527
J Gastrointest Surg. 2019 Mar;23(3):484-491
pubmed: 29980977
Ann Surg Oncol. 2016 Jan;23(1):244-9
pubmed: 26111625
Neuroendocrinology. 2016;103(2):125-38
pubmed: 26758972
Br J Surg. 2012 Nov;99(11):1480-6
pubmed: 22972490
Neuroendocrinology. 2016;103(2):172-85
pubmed: 26731013
Neuroendocrinology. 2017 Apr 13;105(3):295-309
pubmed: 28402980
J Gastrointest Surg. 2019 May;23(5):1044-1054
pubmed: 30671800
J Surg Oncol. 2019 Nov;120(6):926-931
pubmed: 31396982
Endocrinol Metab Clin North Am. 2011 Mar;40(1):1-18, vii
pubmed: 21349409
N Engl J Med. 2014 Jul 17;371(3):224-33
pubmed: 25014687
Endocr Relat Cancer. 2010 Oct 05;17(4):909-18
pubmed: 20702725